Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.

Autor:	Choi KY; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Republic of Korea., Kim HI; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Republic of Korea., Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Yoo KH; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, Republic of Korea., Park YB; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea., Kim Y; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, Republic of Korea., Lee SE; Respiratory, Medical Affairs, Boehringer-Ingelheim Korea, Seoul, Republic of Korea., Kim JA; Real-World Solutions, IQVIA Korea, Seoul, Republic of Korea., Hwang YI; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Republic of Korea.
Jazyk:	angličtina
Zdroj:	International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2024 Jul 16; Vol. 19, pp. 1661-1671. Date of Electronic Publication: 2024 Jul 16 (Print Publication: 2024).
DOI:	10.2147/COPD.S448492
Abstrakt:	Background: COPD causes substantial economic burden on healthcare. Alternative treatment strategies for COPD can be associated with different costs dependent upon their relative safety and effectiveness. We compared costs and healthcare resource utilization (HCRU) associated with LAMA or LABA/ICS initiation. Methods: Using the Korean National Health Insurance Service database, we enrolled COPD patients initiating treatment with LAMA or LABA/ICS between January 2005 and April 2015. Propensity score matched individuals were compared on all-cause and COPD-related medical costs and HCRU over a three-year follow-up period. Results: A total of 2444 patients were enrolled in each treatment group. LAMA group was associated with significantly lower costs than LABA/ICS group, both in all-cause (403.08 vs 474.50 USD per patient per month [PPPM], cost ratio 1.18, 95% confidence interval [CI]=1.10-1.26, p <0.0001) and COPD-related (216.37 vs 267.32 USD PPPM, cost ratio 1.24, 95% CI=1.13-1.35, p <0.0001) medical costs. All-cause HCRU was not significantly different between groups, while COPD-related HRCU was higher in LAMA group (0.66 vs 0.60 medical visits PPPM, p <0.0001). Conclusion: COPD patients initiating treatment with LAMA were associated with lower all-cause and COPD-related medical costs than those starting with LABA/ICS despite the similar all-cause HCRU and higher COPD-related HCRU. Initiation with LAMA is a cost-efficient option for the treatment of COPD. Competing Interests: Chin Kook Rhee received consulting and lecture fees from Merck & Co., Inc., AstraZeneca plc, GSK plc, Novartis AG, Takeda Pharmaceutical Company Limited, Mundipharma International Limited, Boehringer-Ingelheim Korea, Teva Pharmaceutical Industries Ltd., Sanofi S.A., and Bayer AG. Kwang Ha Yoo has conducted clinical trials on Asthma, COPD, and Pneumonia with GSK plc, AstraZeneca plc, Boehringer-Ingelheim Korea, Novartis AG, Takeda Pharmaceutical Company Limited, Nycomed, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mundipharma International Limited, Hyundai Pharmaceutical Co., Ltd., Anguk Pharmaceutical Co., Ltd., Chong Kun Dang Holdings Corp., Hanmi Pharm Co., Ltd., and Hanlim, Pharm Co., Ltd. He received consulting fees from GSK plc, AstraZeneca plc, Boehringer-Ingelheim Korea, Novartis AG, Mundipharma International Limited, Anguk Pharmaceutical Co., Ltd., Chong Kun Dang Holdings Corp., Hanmi Pharm Co., Ltd., and Hanlim Pharm Co., Ltd. Yong Bum Park received consulting and lecture fees from AstraZeneca plc, GSK plc, Novartis AG, Mundipharma International Limited, Boehringer-Ingelheim Korea, and Sanofi S.A. Youlim Kim received consulting and lecture fees from Merck & Co., Inc., GSK plc, Boehringer-Ingelheim Korea, and Hanlim Pharm Co., Ltd. Yong Il Hwang has conducted clinical trials on Asthma, COPD, and bronchitis with GSK plc, AstraZeneca plc, Boehringer-Ingelheim Korea, Novartis AG, Anguk Pharmaceutical Co., Ltd., Chong Kun Dang Holdings Corp., Hanmi Pharm Co., Ltd., and Hanlim Pharm Co., Ltd. He received consulting fees from GSK plc, AstraZeneca plc, Boehringer-Ingelheim Korea, Novartis AG, Anguk Pharmaceutical Co., Ltd., Chong Kun Dang Holdings Corp., Hanmi Pharm Co., Ltd., and Hanlim Pharm Co., Ltd. So Eun Lee is an employee of Boehringer-Ingelheim Korea. Jung-Ae Kim is an employee of IQVIA Korea. The authors report no other conflicts of interest in this work. (© 2024 Choi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu